MedTrace Logo

Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration

NCT06223074 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-04-03

No results posted yet for this study

Summary

This Clinical Trial evaluates the nasal administration of Methylprednisolone as a treatment strategy for Acute Relapses in Multiple Sclerosis

Conditions

  • Multiple Sclerosis Relapsing Remitting
  • Treatment

Interventions

OTHER

IV Methylprednisolone administration

Group 1 will receive 1g methylprednisolone IV for 3 or 5 days, according to the severity of the relapse

DRUG

Nasal Methylprednisolone (MT)

Group 2 will receive the dose intranasal equivalent to 1g of methylprednisolone for 3 or 5 days according to the severity of the relapse

Sponsors & Collaborators

  • Instituto Nacional de Neurología y Neurocirugía

    collaborator UNKNOWN

  • Universidad Nacional Autonoma de Mexico

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-09
Primary Completion
2026-02-25
Completion
2026-07-05

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06223074 on ClinicalTrials.gov